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In vaccine studies for infectious diseases such as human immun-
odeficiency virus (HIV), the frequency and type of contacts between
study participants and infectious sources are among the most in-
formative risk factors, but are often not adequately adjusted for in
standard analyses. Such adjustment can improve the assessment of
vaccine efficacy as well as the assessment of risk factors. It can be at-
tained by modeling transmission per contact with infectious sources.
However, information about contacts that rely on self-reporting by
study participants are subject to nontrivial measurement error in
many studies. We develop a Bayesian hierarchical model fitted us-
ing Markov chain Monte Carlo (MCMC) sampling to estimate the
vaccine efficacy controlled for exposure to infection, while adjusting
for measurement error in contact-related factors. Our method is used
to re-analyze two recent HIV vaccine studies, and the results are
compared with the published primary analyses that used standard
methods. The proposed method could also be used for other vaccines
where contact information is collected, such as human papilloma virus
vaccines.
1. Introduction. Two randomized multi-center Phase III preventive HIV
vaccine trials were conducted to evaluate the efficacy of two versions of
AIDSVAX, a recombinant glycoprotein 120 (rgp120) vaccine developed by
VaxGen and designed to provide protective immunity by inducing antibody
response. One trial (VAX004) was conducted in adults at risk of sexual trans-
mission in North America and the Netherlands, launched in June, 1998, and
the other (VAX003) in injecting drug users (IDUs) in Bangkok, Thailand,
started in March, 1999. In analyses using Cox proportional hazards models,
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the vaccine has been shown to be noneffective in Gurwith et al. (2005) for
VAX004 and in Pitisuttithum et al. (2006) for VAX003.
A general definition of vaccine efficacy is VE = 1 − RR, where RR is
the relative risk of infection for a vaccinated subject compared to that
for a control subject. Depending on how risk is defined, various VE mea-
sures can be derived. The most frequently used measures were classified by
Halloran, Struchiner and Longini (1997) into two categories: conditional on
exposure to infection and unconditional, that is, whether the measure is
controlling for the frequency and type of contacts that lead to transmission.
A contact can be defined as one sexual act of a certain type in the context
of VAX004 and as one act of sharing a needle for drug injection in VAX003.
The VE measure used in Gurwith et al. (2005) and in Pitisuttithum et al.
(2006) falls in the unconditional category. It is of public health interest to re-
analyze the two vaccine trials using a VE measure conditional on exposure
to infection.
For proper inference conditional on exposure to infection, measurement er-
ror in exposure factors should be taken into account. For example, the num-
bers of needle-sharing acts are often under-reported when IDUs are inter-
viewed [Hudgens et al. (2002)]. Thus, methods depending solely on reported
exposure information could be inappropriate. To handle the problem of mea-
surement error, many methods have been introduced [Carroll, Ruppert and
Stefanski (1995)]. In the nonparametric setting, Fan and Truong (1993) ex-
plored the properties of globally consistent nonparametric regression using
deconvolution kernels. Cook and Stefanski (1994) and Carroll et al. (1996)
developed the simulation extrapolation method that imposes no assump-
tion on the covariates measured with error and uses resampling to detect
the trend of measurement error. Richardson and Green (1997) discussed the
use of mixture priors for covariates measured with error in the Bayesian
framework, and this method was extended to epidemiological studies with
a validation set [Richardson et al. (2002)]. In these two vaccine trials, the
exposure factors that are subject to measurement error and that are most
vital to parameter estimation are the frequencies and the types of contacts.
In this paper we develop a Bayesian framework under the simple assump-
tion of conditional independence [Richardson and Gilks (1993)] for infec-
tious disease incidence data with contact frequency and type recorded for
each observation. Using this Bayesian model, we re-analyze the data from
the two AIDSVAX trials. Our primary focus is to estimate the transmission
probability and vaccine efficacy per infectious contact, while adjusting for
measurement error in contact frequency and type. In addition, these studies
provide information to address the following questions that are useful for
understanding HIV transmission:
• Is VE modified by the baseline behavioral risk profile?
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Table 1
Two randomized multi-center trials conducted for evaluating the efficacy of AIDSVAX,
a recombinant glycoprotein 120 HIV-1 vaccine
VAX004 VAX003
Time of trial 1998–2002 1999–2003
Location North America and The Netherlands Bangkok, Thailand
Type of transmission Sexual acts Sharing needles for drug injection
Population size 5403 2527
Male 5095 (94%) 2361 (93%)
Female 308 (6%) 166 (7%)
Randomization ratio
(vaccine:placebo) 2:1 1:1
Infected/Randomized
Placebo 127/1805 105/1260
Male 123/1704 101/1170
Female 4/101 4/90
Vaccine 241/3598 106/1267
Male 239/3391 100/1191
Female 2/207 6/76
HIV-1 subtypes
B 100% 33 (78%)
E 0 164 (16%)
Untypeable 0 14 (6%)
• Is the use of condoms in sexual contacts protective?
• Is sharing needles more risky in prison compared to in the general public?
• Is one subtype of HIV more infectious than another subtype via shared
needle injection?
The results are compared to those obtained in Gurwith et al. (2005),
Pitisuttithum et al. (2006) and Hudgens et al. (2002).
2. Data description. Basic characteristics of the two trials are presented
in Table 1. The two trials had similar designs except the ratio of vaccine
to placebo recipients. Each subject was enrolled free of HIV infection and
received seven injections (study vaccine or placebo) at months 0, 1, 6 and
every six months thereafter up to month 30. At each immunization visit
and the final visit at month 36, antibody assays of blood samples were
performed, and exposure factors, adverse events and social harm events for
each participant in the past six months were collected. The primary endpoint
of the trials was the detection of HIV-1 infection that is defined as both a
positive HIV-1 enzyme immunoassay antibody test and the development of
at least two new nonvaccine bands on confirmatory HIV immunoblot.
For trial VAX004, in addition to vaccine status, exposure factors were col-
lected in the form of sexual contact frequencies categorized by the behavioral
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type of the contact (vaginal, oral or anal), gender of the partner, the infec-
tion status of partners reported by the subject (HIV-positive, HIV-negative
or unknown), and condom use. To reduce the dimension of parameters, we
ignore the effects of behavioral type and gender on transmission probabili-
ties by summing the frequencies over the corresponding categories. As the
study participants were mostly men that have sex with men (MSM), with
females accounting for only 6% of the population and 1.6% of the infections,
we are largely assessing transmission via MSM contacts.
For trial VAX003, the exposure factors of interest are the frequency of
injections, the fraction of injections using needles shared with other people,
the history of injection in jail or prison (incarceration injection), and the
vaccine status. Since one of two HIV-1 subtypes (E and B) was found for
most infections, it is possible to estimate the transmission probability and
vaccine efficacy for each of the two subtypes, given that reasonable estimates
of the prevalences of these subtypes among the IDUs in Bangkok, Thailand,
are available. Contact information collected in this study is not as detailed
as in VAX004. Both the injection frequency and the fraction using shared
needles were reported as a few categories instead of numbers. There are
four categories for the injection frequency (none, < 1/week, ≥ 1/week but<
1/day, and ≥ 1/day), to which we assign values 10−10/day, 0.5/week, 4/week
and 1/day respectively. There are five categories for the fraction of injections
using shared needles (none, occasionally, half of the time, most and always),
to which we assign values 0.5%, 15%, 50%, 85% and 99.5% respectively.
3. Methods.
3.1. Model structure. Following Richardson and Gilks (1993), we specify
three submodels for our Bayesian analysis of the measurement error problem:
the regression submodel, the measurement error submodel and the prior
submodel. In the type of study we are considering, risk factors and infection
status are obtained for each subject over consecutive six-month intervals.
Let N be the total number of study participants and Ti be the number of
intervals of subject i, i= 1, . . . ,N . We use data collected from month 6 to
month 36, excluding month 0 as an adjustment for left truncation. Visits
after the first with positive HIV detection are also excluded from analysis.
For notational convenience, we identify the tth interval of subject i by (i, t).
3.1.1. The regression submodel. Let p0 be the baseline transmission prob-
ability per infectious contact. An infectious contact refers to a contact
with an infectious source. Let nit be the number of contacts and xitj =
(xitj1, . . . , xitjK)
τ be the vector of K covariates associated with the jth con-
tact in interval (i, t), j = 1, . . . , nit. The covariates associated with a contact
may include characteristics of the subject (e.g., vaccine status), the partner
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(e.g., infection status) and the contact itself (e.g., condom use, incarceration,
etc.). To associate the transmission probability with covariates, we consider
a logit model:
p(xitj) = logit
−1(logit(p0) +x
τ
itjθ),(1)
where θ = (θ1, . . . , θK)
τ is the coefficient vector with the interpretation that
exp(θk) is the increment in odds of transmission per unit increase in xitjk or
the odds ratio (OR) for xitjk = 1 relative to xitjk = 0 if xitjk is binary. Other
regression submodels such as the complementary log-log could also be used.
Also frequently used is the multiplicative submodel p(xitj) = p0 exp{x
τ
itjθ}.
However, it is sometimes difficult to guarantee p(xitj)< 1 when p0 and θ are
simultaneously sampled. In the context of the two AIDSVAX trials, we use
ORvac , ORcon and ORinc to denote the odds ratios of transmission per in-
fectious contact for vaccination, condom use and incarceration, respectively.
The probability of escaping infection in interval (i, t) is
Qit =
nit∏
j=1
(1− p(xitj)pi(xitj)),(2)
where pi(xitj) is the prevalence of infectious contacts among all contacts with
covariates xitj . As p(xitj) and pi(xitj) always appear as a product, they are
not estimable at the same time, and pi(xitj) is often assumed known and
evaluated from either literature or the data.
As mentioned in the introduction, different measures can be used for vac-
cine efficacy, depending on the definition of relative risks. A natural choice
is the VE per infectious contact with the risks being transmission probabili-
ties per infectious contact as given in (1). However, the relative risk obtained
from transmission probabilities per infectious contact depends on not only
the vaccine status but also other covariates. Such dependency may not ex-
ist in different models. For example, if we assume a multiplicative model
p(xitj) = p0 exp(x
τ
itjθ), the VE per infectious contact will depend solely on
the vaccine status. For the logit model, the dependency could also be mini-
mal if p(xitj) is small, where we have VE per infectious contact ≈ 1−ORvac .
The approximation holds for the contact types we consider here, and thus,
we report 1−ORvac as the VE per infectious contact for the data analysis.
Expressions (1) and (2) provide a general form for the regression sub-
model. The exact form is specific to each study, depending on the covariates
under consideration, and is described below.
The North America and Netherlands trial (VAX004). For trial VAX004,
we are interested in the effects of vaccine and condom usage. Let vi indicate
the vaccine status (1: yes, 0: no) and citj indicate the condom use (1: yes,
0: no) for the jth sexual contact in interval (i, t). Let p0 be the transmis-
sion probability for a sexual contact without a condom between a placebo
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recipient and an infected partner. We assume the prevalence, pi, of HIV in
contacts is identical for all intervals and is known. The escape probability
for interval (i, t) is given by
Qit =
nit∏
j=1
(1− p(vi, citj)pi) = (1− p(vi,1)pi)
mit(1− p(vi,0)pi)
nit−mit ,(3)
where p(vi, citj) = logit
−1(logit(p0) + θvvi + θccitj), θv and θc are the effects
of the vaccine and condom use, andmit =
∑nit
j=1 citj , the total number of con-
tacts with a condom. The probability distribution of the final transmission
status, yit (1: infection, 0: escape), is then
Pr(yit|nit,mit, vi;p0, θv, θc) =Qit
1−yit(1−Qit)
yit .(4)
The Thai trial (VAX003). For this trial, we consider vaccine status, incar-
ceration history of the subject and needle-sharing as covariates. Let p0 be
the baseline probability of infection by an injection using a needle shared
with an HIV-infected person. Let ui denote whether the subject had incar-
ceration injection (1: yes, 0: no) during the study, and sitj denote whether
the injection was using a shared needle (0: yes, 1: no). Also define θv, θu
and θs as the effects of the covariates, respectively. We assume that injec-
tions using nonshared needles were not infectious. That is, θs = −∞, and
the regression submodel is built solely on the mit =
∑nit
j=1(1− sitj) contacts
using shared needles. The probability of escaping infection in interval (i, t)
is given by
Qit =
nit∏
j=1
(1− p(vi, ui, sitj)pi) = (1− p(vi, ui,0)pi)
mit ,(5)
where p(vi, ui, sitj) = logit
−1(logit(p0)+θvvi+θuui+θssitj). The probability
distribution of the final transmission status is the same as (4).
As the HIV subtype was determined for most infected subjects, it is pos-
sible to estimate the transmission probability and vaccine efficacy for each
subtype. Let p
(e)
0 (p
(b)
0 ) be the baseline probability of infection by an injection
using a needle shared with somebody infected with HIV of subtype E (B),
θ
(e)
v (θ
(b)
v ) be the vaccine effects against transmission of subtype E (B), and
pi(e) (pi(b)) be the prevalence of people infected with subtype E (B) among
the IDU population. The probabilities of escaping infection from injections
using needles shared with infected partners of subtype E and subtype B,
respectively, are given by
Q
(e)
it = (1− logit
−1(logit(p
(e)
0 ) + θ
(e)
v vi + θuui)pi
(e))mit
and
Q
(b)
it = (1− logit
−1(logit(p
(b)
0 ) + θ
(b)
v vi + θuui)pi
(b))mit .
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We assume transmission of subtype E is independent of transmission of sub-
type B. As infection by both subtypes is rare, we assume an infected subject
typed as E (B) must have escaped transmission from infectious contacts of
subtype B (E). The probability distribution of the final transmission status
can be expressed as
Pr(yit, subtype |mit, vi, ui;p0, θv, θu)
(6)
=


Q
(e)
it Q
(b)
it , yit = 0,
Q
(b)
it (1−Q
(e)
it ), yit = 1, subtype = E,
Q
(e)
it (1−Q
(b)
it ), yit = 1, subtype = B,
1−Q
(e)
it Q
(b)
it , yit = 1, subtype = U,
where “U” stands for “Untypeable.”
3.1.2. The measurement error submodel. We consider two types of ex-
posure information that are measured with error, the total number of con-
tacts, nit, and the number of a particular subset of contacts, mit. Let n˜it
and m˜it be the measured values of nit and mit, respectively. As data in
the form of counts over time periods often arise from a Poisson process,
we assume a Poisson distribution for the true number of contacts nit and
an over-dispersed Poisson distribution for the measured number n˜it during
a time interval of length lit, given the contact rate λit. The reason for an
over-dispersion structure is that we want some correction for the potentially
under- or over-reported number of contacts, for example, the number of
sexual contacts in a single interval was reported as thousands by several
subjects in trial VAX004. The histograms of reported contact rates in Fig-
ure 1(a) for VAX004 and Figure 1(c) for VAX003 suggested either gamma
or log-normal distributions. We use the log-normal distribution for illustra-
tion, but compare both in the data analyses. Define ni = (ni1, . . . , niTi)
τ ,
mi = (mi1, . . . ,miTi)
τ , n˜it = (n˜i1, . . . , n˜iTi)
τ , m˜i = (m˜i1, . . . , m˜iTi)
τ and λi =
(λi1, . . . , λiTi)
τ . Let 1 and J denote the vector and matrix, respectively, with
all elements being 1, and let I denote the identity matrix. The dimensions
of 1, J and I are clear from the context and are thus suppressed. We choose
the following measurement error structure for nit:
λi ∼ Log-Normal(µ1, σ
2(ρJ + (1− ρ)I)),
nit ∼ Poisson(λitlit),
(7)
δit ∼Gamma(φ,λitlit/φ),
n˜it ∼ Poisson(δit).
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An exchangeable within-subject correlation structure is assumed for the con-
tact rates, λi, but other correlation structures could be considered. The mag-
nitude of correlation among elements of λi is measured by ρ, 0≤ ρ≤ 1, the
correlation coefficient for log(λi). We assume unbiasness for the measure-
ment error, as E(n˜it|λit) = λitlit =E(nit|λit). The over-dispersion is reflected
by VAR(n˜it|λit) = λitlit(1 + λitlit/φ) and is generated by adding the layer
of δi = (δi1, . . . , δiTi)
τ . The degree of over-dispersion decreases as φ goes to
infinity. By our assumption, nit is conditionally independent of n˜it given
the contact rate λit. Zero values of n˜it are allowed for intervals in which
infections happened since only nit is required to be nonzero.
Given nit and n˜it, it is natural to choose binomial distributions for both
the true numbermit and the measured number m˜it based on a beta-distributed
proportion ξit, which is also suggested by the histograms of reported propor-
tions of contacts with condom use in Figure 1(b) for VAX004 and contacts
with needle-sharing in Figure 1(d) for VAX003. Define Φ(·) as the standard
Fig. 1. (a) Reported sexual contact rates in VAX004. Values larger than 5/day (<0.1%)
are truncated in the graph but not in the analysis. The vertical line segments indicate the
location of values between 1 and 5. (b) Reported proportions of condom use in VAX004.
(c) Reported injection rates in VAX003. (d) Reported proportions of shared needles in
VAX003.
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normal cumulative distribution function (CDF) and Ψ(·|α,β) as the beta
CDF. We have
ξit ∼ Beta(α,β),
mit ∼ Binomial(nit, ξit),
m˜it ∼ Binomial(n˜it, ξit),(8)
Φ(εit) = Ψ(ξit|α,β),
εi ∼N(0, γJ + (1− γ)I),
where εi = (εi1, . . . , εiTi)
τ . We use a standard normal copula to model the
within-subject correlation among ξi = (ξi1, . . . , ξiTi)
τ , the proportions of con-
tacts in a subcategory (condom use or needle-sharing). This copula is formed
by generating a standard normal random vector εi with an exchangeable
correlation structure, the correlation coefficient being γ, and transforming
it to a uniform random vector using Φ on each component. The uniform
random vector is then transformed to ξi using Ψ
−1 on each element. The
ξi generated in this way has marginal CDF Ψ(·|α,β) and an exchangeable
correlation structure. While the correlation coefficient for ξi is not the same
as that for εi, they share the same rank correlation because the CDFs are
monotonic. Note that the log-normal distribution can be viewed as a special
case utilizing the standard normal copula. Conditional on nit, n˜it and ξit,
mit and m˜it are independent.
3.1.3. The prior submodel. We use the following priors for p0, θ and
hyperparameters:
µ∼ 1,
σ2 ∼
1
σ2
,
ρ∼Uniform(0,1),
φ∼
[
lnΓ′′(φ)−
1
φ
]1/2
,
(9)
(α,β)∼ [lnΓ′′(α) lnΓ′′(β)− lnΓ′′(α+ β)(lnΓ′′(α) + lnΓ′′(β))]1/2,
γ ∼Uniform(0,1),
θk ∼Normal(0, d
2
k), k = 1, . . . ,K,
p0 ∼Uniform(ap, bp),
where {dk :k = 1, . . . ,K}, ap and bp are assumed known, and lnΓ
′′(·) is the
trigamma function. Jeffreys’ noninformative priors are used for µ, σ2, φ and
(α,β).
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Our choice of a relatively wide range (ap, bp) is guided by the maximum
likelihood estimate (MLE) of p0 obtained solely from the regression sub-
model. To use this simple likelihood method, we assume nit = n˜it, and mit
is estimated by nit ×
∑
i,t m˜it/
∑
i,t n˜it for VAX003. The same assumption
of a common proportion of shared needles was employed in Hudgens et al.
(2002). However, one will not be able to differentiate the condom effect
with a common proportion of condom use, and thus, we assume mit = m˜it
additionally to obtain the MLE of p0 for VAX004.
A normal prior N(0, d2k) is reasonable for covariate effects because we let
the data drive the 95% credible sets away from the null value if strong effects
exist. The values of {dk :k = 1, . . . ,K} are set relatively large, for example,
2, to provide a wide domain for the odds ratios.
3.2. Posterior distributions. Bayesian inferences are based on posterior
distributions of all unknown parameters and latent variables given the data
and known parameters, which are derived from the prior and conditional
distributions stated in the previous section. Let y = (yτ1 , . . . ,y
τ
N )
τ be the
vector of observed infection status, where yi = (yi1, . . . , yiTi)
τ , and let x=
(xτ1 , . . . ,x
τ
N )
τ , where xi = (x
τ
i1, . . . ,x
τ
iTi
)τ and xit = (xit1, . . . ,xitnit)
τ , be the
observed covariate matrix for all intervals. Similarly, define n, n˜, m, m˜, λ,
δ, ξ and ε as the vectors of nit, n˜it, mit, m˜it, λit, δit, ξit and εit, t= 1, . . . , Ti,
i = 1, . . . ,N . Let f(·) denote the probability density function (PDF) for
continuous variables and the probability mass function (PMF) for discrete
variables. The joint posterior distribution of all unknown parameters and
latent variables is proportional to the joint full probability of the unknown
parameters, latent variables and the data:
f(n,m,δ,λ,ε,ξ, p0,θ, φ,µ,σ
2, ρ,α,β, γ|y,x, n˜,m˜)
∝ f(y,n, n˜,m,m˜,δ,λ,ε,ξ, p0,θ, φ,µ,σ
2, ρ,α,β, γ|x)
= f(y|n,m, p0,θ,x)× f(m˜|n˜,ξ)× f(n˜|δ)× f(m|n,ξ)
(10)
× f(n|λ)× f(δ|λ, φ)× f(λ|µ,σ2, ρ)× f(ε|γ)
× f(µ)× f(σ2)× f(ρ)× f(φ)× f(α)× f(β)
× f(γ)× f(p0)× f(θ),
where ξ exists as a function of ε given in (8), and known hyper-parameters
are suppressed.
To illustrate the MCMC algorithm used to obtain the joint posterior dis-
tribution of all parameters, we use VAX004 as an example and give the
technical details in the appendix. In summary, we use the following strate-
gies:
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• n, m, δ, µ and σ2 are sampled directly from their full conditional distri-
butions.
• For λ, ξ and ε, the full conditional distribution is a product of several
regular density functions, and we use Metropolized independence sampling
with each density sequentially serving as the proposal distribution.
• The random-walk style Metropolis–Hastings algorithm is used for sam-
pling all other parameters.
4. Application. In the following, we report the posterior medians fol-
lowed by the 95% credible sets (CS) for parameters in the Bayesian model,
and make comparisons with point estimates followed by the 95% confidence
intervals (CI) from the literature when appropriate.
4.1. VAX004: HIV transmission by sexual contacts. At each semiannual
follow-up visit in trial VAX004, subjects were asked to classify the sexual
contacts by the infection status of their partners, that is, positive, nega-
tive or unknown, based on their knowledge. HIV prevalence among partners
reported as HIV-negative may be less than that among partners reported
as HIV-positive. However, an exploratory analysis using a simple likelihood
method showed that the probability of infection per contact was not differ-
ent across the three types of partner infection status reported by the study
participants. Hence, we assume a common prevalence pi of infection among
all partners and estimate it by 0.06, the proportion of reported contacts with
positive partners among all contacts in the study population. In addition to
the analysis for the overall study population, we performed a stratified anal-
ysis by classifying the study population into three subgroups corresponding
to low, medium and high baseline (month 0) risk levels. We allow the trans-
mission probability and vaccine effect to vary across, but assume that other
parameters are not affected by, risk levels. The baseline risk levels are deter-
mined by a behavioral risk score ranging from 0 to 7, with 0 as low, 1–3 as
medium, and 4–7 as high. The behavioral score is derived from nine base-
line risk factors that are highly predictive of HIV infection [Gurwith et al.
(2005)].
Table 2 gives the results regarding transmission probabilities and VEs
for VAX004. The vaccine did not show a significant effect, reducing the
risk of infection per infectious contact by about 7% for the overall study
population which is not statistically different from 0. Neither did the low-
risk and medium-risk subgroups show any significant vaccine effect. However,
we do observe a significant VE of 0.56 (95% CS:0.22, 0.75) in the high-risk
subgroup, as the associated 95% CS excludes 0. The pattern that higher
baseline risk tends to be associated with higher vaccine efficacy was also
identified in Gurwith et al. (2005) via a Cox proportional hazards model for
grouped times, where they reported an estimate of 0.06 (95% CS:−0.17,0.24)
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Table 2
VAX004: Summary of the posterior distributions of the transmission probability and the
vaccine efficacy per infectious sexual contact for the overall study population and by
baseline risk level, compared to the standard analysis
Risk
level
p VE (Bayesian) VE (Coxa)
Totalb Infected Median 95% C.S. Median 95% C.S. Estimate 95% C.I.
Overall 8772 368 0.0056 0.0044, 0.0071 0.069 −0.15, 0.26 0.06 −0.17, 0.24
Low 3605 57 0.0020 0.0010, 0.0036 −0.23 −1.48, 0.35 −0.48 −1.93, 0.26
Middle 4546 229 0.0054 0.0041, 0.0071 0.02 −0.28, 0.25 0.03 −0.25, 0.25
High 621 82 0.020 0.013, 0.030 0.56 0.22, 0.75 0.43 0.04, 0.66
aResults based on Cox proportional hazards model in Gurwith et al. (2005).
bTotal number of six-month intervals.
Table 3
VAX004: Summary of the posterior distributions of other parameters for the overall
study population
Posterior
Quantiles ORcon φ µ σ
2 ρ α β γ
Median 1.44 1.66 −2.54 1.95 0.92 0.30 0.29 0.65
2.5% 1.06 1.61 −2.58 1.87 0.91 0.29 0.28 0.64
97.5% 1.94 1.71 −2.50 2.04 0.92 0.31 0.30 0.67
for VE per six-month interval for the overall study population and 0.43 (95%
CS:0.04, 0.66) for the high-risk subgroup, fairly close to our estimates.
The baseline transmission probability per infectious sexual contact for the
overall study population is 0.0056 (95% CS:0.0044, 0.0071), suggesting that
1000 sexual contacts with HIV-positive partners produce about six infections
on average, without intervention of vaccine or condoms. This probability
increases across risk levels, with the value for the high risk level 10 times
that for the low risk level. A possible reason for the increase in transmission
probability across risk levels is that subjects in higher risk levels might more
likely under-report the number of contacts.
Results for all other parameters are presented in Table 3. Surprisingly,
the reported use of condoms did not seem to be protective with ORcon
estimated as 1.44 (95% CS:1.06, 1.94), suggesting that it increased the odds
of transmission by about 44%. A possible explanation is that the reporting
of condom use might be correlated with certain types of sexual behavior.
A more specific speculation is that subjects in monogamy tended to use
condoms much less frequently and yet had lower risk of infection as compared
to those with multiple partners. We included an indicator for monogamy (on
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average < 2 partners over the study period), but the estimate of ORcon did
not change much (results not shown).
High within-subject correlation is found among the contact rates and
proportions of condom use, with ρ and γ estimated as 0.92 (95% CS:0.91,
0.92) and 0.65 (95% CS:0.64, 0.67) respectively. These correlation parame-
ters indicate the magnitude of, but do not directly measure, the correlation
coefficients among λi and among ξi. Based on posterior medians of µ, σ
2,
α and β, we found that the mean contact rate in this cohort is 0.21 (95%
CS:0.20, 0.22) times per day, and the mean proportion of condom use is 0.51
(95% CS:0.50, 0.52).
If a marginal gamma distribution is assumed for λi, we use the same cop-
ula technique used for ξi to introduce within-subject correlation. Changing
the distribution of the contact rate from log-normal to gamma does not af-
fect the estimates appreciably except for a slight increase in φ and decrease
in ρ. We compare predicted population-level means and variances of the re-
ported number of contacts yielded by the two distributions to the observed
values, shown in Figure 2(a)–(c). While the gamma distribution gives a pre-
dicted mean closer to the observed mean, the log-normal distribution gives
a more realistic standard deviation. The heavier tail of the log-normal dis-
tribution can better catch extreme reported values. We choose not to ignore
the extreme reported values, and therefore, all above results for VAX004 are
based on the log-normal distribution for the contact rate.
While we believe that our prior assumptions over most parameters are
noninformative or toward-null, we performed a brief sensitivity analysis by
changing the prior distribution of p0. We impose a strong beta prior with
mean 0.0073 and standard deviation 0.001, instead of Uniform(0.0001,0.1),
on p0. The posterior estimates increase to 0.0063 (0.0052,0.0075) for p0 and
0.12 (−0.08,0.29) for VE, and decrease to 1.28 (0.99,1.68) for ORcon , all
changes being mild. A higher prior mean of p0 will cause more substantial
changes in the same directions.
4.2. VAX003: HIV transmission among IDUs using shared needles. In
the Bayesian probability structure for trial VAX003, the over-dispersion
structure and the related parameters, φ and δit, are dropped, that is, we
assume n˜it ∼Poisson(λit). The reason is that there is not sufficient informa-
tion about over-dispersion with only four categories for the contact rate. We
stratify the shape and scale parameters by incarceration injection history
(ui) for both injection rate (λit) and the proportion of needle sharing (ξit),
an attempt to control for confounding factors when we evaluate the effect of
incarceration injection history on the transmission probability. The preva-
lence of HIV among IDUs in Bangkok was around 30% [Kitayaporn et al.
(1998)]. It was estimated that the relative prevalence between subtypes E
and B was growing at a decreasing rate between 1998 and 2000, and reached
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Fig. 2. (a) Reported number of sexual contacts in VAX004. Values larger than 1000
are truncated. The vertical line segments indicate the location of values between 200 and
1000. (b) Predicted number of sexual contacts in VAX004, assuming gamma distribution
for contact rate. (c) Predicted number of sexual contacts in VAX004, assuming log-normal
distribution for contact rate. (d) Reported number of injections in VAX003. (e) Predicted
number of injections in VAX003, assuming gamma distribution for injection rate. (f) Pre-
dicted number of injections in VAX003, assuming log-normal distribution for injection
rate.
70%:30% in 2000 [Kitayaporn et al. (1998), Hudgens et al. (2002)]. Based
on this information, the average relative prevalence most likely is between
0.7:0.3 to 0.8:0.2. We use pi(e) = 0.75× 0.3 = 0.225 and pi(b) = 0.075 for anal-
yses stratified by subtype.
We performed additional analyses stratified by two baseline behavioral
risk levels defined in Pitisuttithum et al. (2006). A subject (and all his six-
month intervals) is classified into the high baseline risk level if 2 or more
of the following risk factors were present at visit 0: use of injection drugs
regularly, use of injection drugs daily or weekly, use of injection drugs with
shared needles, history of incarceration during the past 6 months, partner
was an IDU, or shared needles with partner. Otherwise, the subject is clas-
sified into the low risk level.
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Table 4
VAX003: Summary of the posterior distributions of the transmission probability and the
vaccine efficacy per infectious needle-sharing act for the overall study population and by
baseline risk level and HIV subtype, compared to the standard analysis
Risk
level
Sub-
type
Infect-
edc
p VE (Bayesian) VE (Coxa)
Totalb Median 95% C.S. Median 95% C.S. Estimate 95% C.I.
Overall 13797 206 0.026 0.021, 0.031 −0.08 −0.43,0.20 0.001 −0.31, 0.24
E 160 0.028 0.022, 0.034 −0.12 −0.52,0.17 −0.014 −0.38, 0.25
B 32 0.019 0.012, 0.029 0.18 −0.57,0.60
E/B 1.45 0.91, 2.39
Low 6622 80 0.033 0.024, 0.045 0.06 −0.49,0.41
E 55 0.034 0.022, 0.048 0.04 −0.66,0.42
B 16 0.032 0.015, 0.058 0.18 −1.33,0.67
E/B 1.06 0.51, 2.54
High 7175 126 0.023 0.017, 0.029 −0.10 −0.60,0.23
E 105 0.025 0.019, 0.032 −0.21 −0.77,0.19
B 16 0.015 0.008, 0.026 0.34 −0.63,0.77
E/B 1.68 0.92, 3.31
aResults based on Cox proportional hazards model in Pitisuttithum et al. (2006).
bTotal number of six-month intervals.
cIntervals for 5 subjects infected by visit 0 (E:4, B:1) are excluded. The 14 untypeable
infections are not shown.
The results for transmission probabilities and vaccine efficacies are pre-
sented in Table 4. None of the VE estimates are significantly different from
0. We estimate the VE per infectious needle-sharing act as −0.08 (95%
CS:−0.43,0.20) for overall transmission and as −0.12 (95% CS:−0.52,0.17)
for subtype E. Although subtype B tends to have a better VE than subtype
E, the difference is not significant. Pitisuttithum et al. (2006) reported simi-
lar VE estimates, 0.001 (95% CI:−0.31,0.24) for the overall IDU cohort and
−0.014 (95% CI:−0.38,0.25) for subtype E, based on a Cox proportional
hazards model for grouped times.
The baseline transmission probability per injection using a needle shared
with an HIV-positive IDU is 0.026 (95% CS:0.021,0.031), suggesting that,
out of 100 such injections, 2.6 on average will transmit the virus. The
subtype-specific baseline transmission probabilities are estimated as 0.028
(95% CS:0.022, 0.034) for p
(e)
0 and 0.019 (95% CS:0.012,0.029) for pˆ
(b)
0 ,
higher than the 0.016 (95% CI:0.012, 0.02) and 0.0063 (95% CI:0.0041,
0.0092) estimated in Hudgens et al. (2002) based on a likelihood method.
It is interesting that the transmission probability per injection is somewhat
higher for the low versus high baseline risk, opposite to the direction ob-
served in VAX004. The ratio of p
(e)
0 to p
(b)
0 , with a posterior median of 1.45
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Table 5
VAX003: Summary of the posterior distributions of other parameters for the overall
study population
With incarceration Without incarceration
Posterior
quantiles
injection history injection history
ORinc ρ γ αλ
a βλ
b α β αλ
a βλ
b α β
Median 0.47 0.50 0.47 0.24 1.87 0.23 1.36 0.20 1.25 0.23 5.28
2.5% 0.30 0.48 0.44 0.21 1.60 0.20 1.12 0.19 1.18 0.22 4.85
97.5% 0.72 0.52 0.51 0.27 2.24 0.26 1.66 0.21 1.32 0.25 5.75
aShape of the gamma distribution for contact rate.
bScale of the gamma distribution for contact rate.
(95% CS:0.91, 2.39), is only marginally different from 1, lower than the 2.48
(95% CI:1.63, 3.88) reported in Hudgens et al. (2002).
Table 5 summarizes estimates for all other parameters. The odds ra-
tio for incarceration injection is estimated as 0.47 (95% CS:0.30, 0.72).
Hudgens et al. (2002) reported a much higher value, 4.47 (95% CI:2.63,
7.19), where a time-varying prevalence ratio with an average about 0.55:0.45
between subtypes E and B and a common proportion of 4% for needle shar-
ing across the whole population were assumed. Among subjects with in-
carceration injection history, the mean injection rate is 0.45 (95% CS:0.37,
0.54) times per day and 14% (95% CS:12%, 17%) involved shared needles.
In contrast, among those without incarceration history, the mean injection
rate is 0.25 (95% CS:0.24, 0.27) times per day and 4.2% (95% CS:4.0%,
4.5%) involved shared needles. The assumption of a common proportion of
needle-sharing in Hudgens et al. (2002) lowers the injection frequency and
proportion of needle-sharing down to the overall level, and consequently in-
creases the adjusted transmission probability for subjects with incarceration
history. In addition, the incarceration injection indicator is defined for each
interval in Hudgens et al. (2002), whereas we define it for each individual.
Posterior estimates of ρ, 0.50 (95% CS:0.48, 0.52), and γ, 0.47 (95% CI:0.44,
0.51), suggest substantial within-subject correlation, though not as high as
those in VAX004.
Similar to VAX004, log-normal and gamma distributions for the injection
rate lead to similar results, with a slight difference in ρ. In Figure 2(d)–(f), we
see that the heavy tail of the log-normal distribution yields extremely large
predicted moments for the reported number of injections and thus makes it
less competitive than the gamma distribution for modeling injection rates
reported in a few categories. Consequently, all results presented for VAX003
are based on the gamma distribution for injection rate.
We performed sensitivity analyses by changing the relative prevalence
pi(e) :pi(b) to 0.7 : 0.3 and 0.8 : 0.2. As expected, the transmission probability
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tends to decrease for subtype E but to increase for subtype B, as the rela-
tive prevalence of subtype E increases. For each subtype and risk level, the
VE estimate changes in the direction opposite to that of the corresponding
transmission probability, but none of the VE estimates differ significantly
from 0. The magnitude of all these changes are relatively small, especially
for subtype E. The estimated transmission probability ratio of subtype E to
subtype B decreases as the relative prevalence of subtype E increases. Par-
ticularly, subtype E becomes statistically more infectious than subtype B
with an estimate of 1.88 (95% CS: 1.18, 3.21) for p
(e)
0 /p
(b)
0 , if the prevalence
of subtype E is as low as 70% among the IDUs.
5. Discussion. We established a Bayesian hierarchical model for ana-
lyzing clinical studies of infectious disease with transmission and exposure
data observed over discrete time intervals. This model provides assessment
of the transmission probability and vaccine efficacy conditioning on an in-
fectious contact, whereas standard methods of analyzing vaccine trials do
not. Assuming conditional independence between observed and true but un-
observed quantities, this model provides an approach to adjustment for the
measurement error in some key risk factors. We used the method to re-
analyze two HIV-1 vaccine trials on populations who are at high risk of
HIV-transmission via sexual contacts or sharing needles for drug injection.
The proposed method could be applied to studies of other vaccines, such as
human papilloma virus vaccines, where contact information is collected.
We obtained estimates of vaccine efficacy similar to the primary study
results, especially for VAX004, confirming the findings of no protective
efficacy. Two factors may contribute to this similarity in VE estimates.
First, the measurement error might be relatively small for the majority
of the study population. Second, our model assumes unbiasness, that is,
E(n˜it|λit) = E(nit|λit) and E(m˜it|λit, ξit) = E(mit|λit, ξit). However, if the
bias trend is similar in both treatment groups, even a model with bias cor-
rection will likely yield a similar VE estimate as well. Despite the similarity,
our hierarchical model provides joint inference on not only the transmission
probability and VE but also the population-level behavioral characteristics
such as the contact rate and proportion of condom use (needle-sharing).
We have assumed an exchangeable structure for within-subject correla-
tion among contact (injection) rates and proportions of condom use (needle-
sharing), using the copula method. A more sophisticated structure may
be considered given sufficient data. Within-subject sample correlation co-
efficients among the logarithm of reported contact rates, {log(n˜it/lit) : t =
1, . . . , Ti}, and among reported proportions of condom use, {m˜it/n˜it : t =
1, . . . , Ti}, in VAX004 do indicate that correlation wanes away as two inter-
vals are further apart, but the variation range is relatively small, 0.3–0.5 for
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the former and 0.45–0.67 for the latter. Therefore, an exchangeable struc-
ture is a reasonable assumption, albeit an autoregressive structure such as
the ARMA(p, q) model [Chib and Greenberg (1994)] may be more realistic.
The range of 0.3–0.5 for {log(n˜it/lit) : t= 1, . . . , Ti} may seem contradictory
to the Bayesian estimate of ρ around 0.9. A plausible explanation is that the
addition of δit to reflect the over-dispersion may attenuate the true correla-
tion among the elements of λi, as the elements of δi are independent given
λi. Consequently, a high correlation among the elements of λi is needed to
yield a moderate marginal correlation among the elements of δi. In fact,
the parameter estimates, especially for transmission probabilities and VEs,
do not change much if we assume intervals within the same subject are in-
dependent. A possible reason is that only the overall magnitude of ni and
mi matter in the estimation of p0 and the VE, and the magnitude mainly
depends on the observed n˜i and m˜i and is much less affected by the correla-
tion. However, we do see that correlation adjustment changes the shape and
scale of the distributions of the contact rate λit and the proportion ξit in a
more noticeable way. For example, without incarceration injection history,
the estimates for the shape parameter β for the proportion of needle-sharing
in VAX003 change from 5.28 (95% CS:4.85, 5.75) to 6.3 (95% CS:5.92, 6.69)
when within-subject independence is assumed.
To adjust for error in self-reported contact information, we assumed a
Poisson process for the true number of contacts and an over-dispersed Pois-
son process for the reported one, and that the two processes are condition-
ally independent given the underlying contact rate. Ideally, validation data
would be available so that the measurement error could be modeled paramet-
rically or without parametric assumptions as in Golm, Halloran and Longini
(1999). The collection of validation data would be useful in future vaccine tri-
als. In this Bayesian framework, a more general bivariate distribution could
be modeled between nit and n˜it given λit or between λit and a latent rate
λ˜it that determines the distribution of n˜it, had validation data been avail-
able on contact frequency. Another form of additional data, replication of
n˜it and m˜it in all or some of the intervals, can also improve model precision
[Carroll, Ruppert and Stefanski (1995)], but the assumption of unbiasness
of n˜it for the true nit has to be retained. A possible parametric utilization
of replication data in our model is to allow for within-interval correlation.
Other than log-normal and gamma distributions, a more flexible option for
modeling the contact rate may be mixture prior densities [Richardson et al.
(2002)]. It is likely that the true number of contacts also comes from an
over-dispersed Poisson process, but whether such a model is identifiable
needs further investigation. When the number of contacts is given as K
categories and K is small, for example, in trial VAX003, the Poisson and
over-dispersed Poisson structure may not be realistic. In that case, a more
flexible probability structure is to assume that nit and n˜it independently
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follow a discrete distribution indexed by pit = (pit1, . . . , pitK)
τ , where pitk
is the probability of falling in the kth category for interval (i, t), and pit ∼
Dirichlet(α) for some random or known vector α.
The model is sensitive to the contact-related information when such in-
formation is limited. For instance, when the value assigned to the “None”
category of the reported proportion of needle-sharing was increased from
0.5% to 5% or higher, we were unable to obtain convergence, likely due
to the lack of curvature supporting the estimation of a beta density. We
emphasize for future studies that, in terms of contact frequency, numbers
are more informative than categories, and more categories are preferred to
fewer. Another factor to which the analyses are sensitive is the prevalence
of infections among partners. While it is impossible to obtain the infection
status of all partners, a validation set of partners randomly selected for ver-
ification of infection would help improve the inference. To alleviate under-
or over-reporting of contact frequency, it is also important to ensure that
study participants understand the definition of a contact, especially when
the study involves multiple contact types. Extremely high frequencies, for ex-
ample, the numbers of sexual contacts that were reported as over thousands
per six-month interval by several participants in VAX004, may indicate mis-
understanding of the definition, and should be verified with the participants
during the follow-up visits. The underlying mechanism of measurement er-
ror in contact-related factors in real studies may never be known, and the
best way to improve the VE estimation is to reduce the error at the data
collection step.
APPENDIX: MCMC METHODS AND RELATED SAMPLING ISSUES
MCMC sampling schemes. We use fdist(·|·) to denote the PDF for con-
tinuous variables or the PMF for discrete variables, and Fdist (·|·) to denote
the CDF of a random variable given parameters. The subscript “dist” could
be “Bin” for binomial, “Pois” for Poisson, “Beta” for beta, “G” for gamma,
“IG” for inverse gamma, “N” for normal and “LN ” for log-normal distribu-
tions. Whether the distribution is univariate or multivariate is determined
by the parameter input.
Sampling nit. Define qi1 = 1 − p(vi,1) as the probability of escaping
infection from a contact protected by condom use, and similarly, define qi0 =
1− p(vi,0) for an un-protected contact. The conditional probability of nit is
20 Y. YANG, P. GILBERT, I. M. LONGINI, JR. AND M. E. HALLORAN
given by
Pr(nit = n|·) =


(λitlit(1− ξit)qi0)
n−mit exp{−λitlit(1− ξit)qi0}
(n−mit)!
, yit = 0,
(λitlit(1− ξit))
n−mit exp{−λitlit(1− ξit)}
(n−mit)!
× [1− qmiti1 q
n−mit
i0 ]/Cit, yit = 1,
where Cit = 1− qi1
mit exp{λitlit(1− ξit)(qi0 − 1)}. When yit = 0, we sample
nit−mit directly from Poisson(λitlit(1− ξit)qi0). When yit = 1, note that the
conditional CDF of nit is
Pr(nit ≤ n|·, yit = 1)
= [exp{λitlit(1− ξit)}FPois(n|λitlit(1− ξit))
(11)
− qi1
mit exp{λitlit(1− ξit)q0}FPois(n|λitlit(1− ξit)qi0)]
× [exp{λitlit(1− ξit)} − qi1
mit exp{λitlit(1− ξit)qi0}]
−1.
As the CDF is a nondecreasing function, we use direct sampling in combina-
tion with binary searching. For example, to sample nit, we generate a value
z from Uniform(0,1); then, the smallest n satisfying Pr(nit ≤ n|·, yit = 1)≥ z
is the sampled value of nit and can be found using binary searching or other
advanced searching methods.
Sampling mit. The conditional probability of mit is
Pr(mit =m|·) =


(
nit
m
)
ξitqi1
ξitqi1+ (1− ξit)qi0
m
×
(
1−
ξitqi1
ξitqi1 + (1− ξit)qi0
)nit−m
, yit = 0,
(
nit
m
)
ξmit (1− ξit)
nit−m × [1− qmi1q
nit−m
i0 ]/Dit, yit = 1,
where Dit = 1− [ξitqi1+(1− ξit)qi0]
nit . When yit = 0, we sample mit directly
from Binomial(nit,
ξitqi1
ξqi1+(1−ξit)qi0
). When yit = 1, we have
Pr(mit ≤m|·, yit = 1)
(12)
=
FBin(m|nit, ξit)− (ξqi1 + (1− ξit)qi0)
nitFBin(m|nit,P)
1− (ξitqi1 + (1− ξit)qi0)
nit ,
where P = ξitqi1ξitqi1+(1−ξit)qi0 . We use the same technique in sampling nit, that
is, direct sampling in combination with binary searching.
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Sampling λit. Define µi = µ1Ti×1 andΣi = σ
2(ρJTi×Ti+(1−ρ)ITi×Ti)).
The likelihood part concerning the contact rate vector λi is given by
Li(λi|·)∝ fLN (λi|µi,Σi)
(
Ti∏
t=1
fG(λit|nit +1, l
−1
it )
)
×
(
Ti∏
t=1
fIG
(
λit
∣∣∣∣φ, litφδit
))( Ti∏
t=1
λit
)
.
To sample λi, we take the following steps:
• First sample λ⋆i from Log-Normal(µi,Σi), and accept it with the proba-
bility
min
(
1,
∏Ti
t=1{fG(λ
⋆
it|nit + 1, l
−1
it )fIG(λ
⋆
it|φ, lit/(φδit))λ
⋆
it}∏Ti
t=1{fG(λit|nit + 1, l
−1
it )fIG(λit|φ, lit/(φδit))λit}
)
.
Update λi with λ
⋆
i if the new sample is accepted;
• Sample a new λ⋆i from
∏Ti
t=1(fG(λ
⋆
it|nit + 1, l
−1
it ), and accept it with the
probability
min
(
1,
fLN (λ
⋆
i |µi,Σi)
∏Ti
t=1{λ
⋆
itfIG(λ
⋆
it|φ, lit/(φδit))}
fLN(λi|µi,Σi)
∏Ti
t=1{λitfIG(λit|φ, lit/(φδit))}
)
.
Update λi with λ
⋆
i if the new sample is accepted;
• Sample a new λ⋆i from
∏Ti
t=1 fIG(λit|φ,
lit
φδit
) and accept it with the prob-
ability
min
(
1,
fLN (λ
⋆
i |µi,Σi)
∏Ti
t=1{λ
⋆
itfG(λ
⋆
it|nit +1, l
−1
it )}
fLN(λi|µi,Σi)
∏Ti
t=1{λitfG(λit|nit + 1, l
−1
it )}
)
.
This cross-sampling procedure is a generalization of the Metropolized in-
dependence sampling algorithm [Chib and Greenberg (1995)]. Liu (1996)
showed that Metropolized independence sampling is superior to rejection
sampling with respect to asymptotic efficiency and ease of computation,
given that the proposal density provides a reasonable coverage over the do-
main of the posterior density. In this case, we have a composite full likelihood
L(x) ∝ f(x)g(x) in which f(x) and g(x) are both ready for sampling. Us-
ing f(x) and g(x) alternately as the proposal density can better cover the
reasonable range of x as compared to using either f(x) or g(x) alone as the
proposal density.
Sampling εi and ξi. Define Υi = γJTi×Ti +(1−γ)ITi×Ti . The likelihood
part concerning εi is given by
Li(εi|·)∝ fN (εi|0,Υi)×
Ti∏
t=1
ξmit+m˜itit (1− ξit)
nit−mit+n˜it−m˜it .(13)
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The above likelihood is expressed in terms of εi, and ξi exists through ξit =
Ψ−1(Φ(εit)|α,β). To express the likelihood in terms of ξi, (13) becomes
Li(ξi|·)∝ exp{−
1
2ε
τ
iΥ
−1
i εi +
1
2ε
τ
i εi}
(14)
×
Ti∏
t=1
fBeta(ξi|α+mit + m˜it, β + nit −mit + n˜it − m˜it),
where εi exists via εit =Φ
−1(Ψ(ξit|α,β)). |
∏Ti
t=1{Φ
−1′(Ψ(ξit))Ψ
′(ξit)}| is the
Jacobian term, and Φ−1
′
(x) = [fN (Φ
−1(x)|0,1)]−1 .
The sampling of εi and ξi proceeds as the following:
• Based on (13), sample ε⋆i from Normal(0,Υi), and accept it with the
probability
min
(
1,
Ti∏
t=1
ξ⋆it
mit+m˜it(1− ξ⋆it)
nit−mit+n˜it−m˜it
ξit
mit+m˜it(1− ξit)nit−mit+n˜it−m˜it
)
,
where ξ⋆it =Ψ
−1(Φ(ε⋆it)). Update εi and ξi if the new sample is accepted;
• Based on (14), sample ξ⋆i from
∏Ti
t=1 fBeta(α+mit+ m˜it, β+(nit−mit)+
(n˜it − m˜it)), and accept it with the probability
min
(
1,
exp{(−1/2)ε⋆i
τ
Υ
−1
i ε
⋆
i + (1/2)ε
⋆
i
τε⋆i }
exp{(−1/2)ετiΥ
−1
i εi + (1/2)ε
τ
i εi}
)
,
where ε⋆it =Φ
−1(Ψ(ξ⋆it)).
Sampling other parameters. Let logλi = (logλi1, . . . , logλiTi)
τ , µi = µ1Ti×1,
and let Ri = ρJTi×Ti + (1− ρ)ITi×Ti such that Σi = (σ
2)Ri.
The following parameters are sampled directly from their full conditional
distributions:
δit|· ∼Gamma
(
n˜it + φ,
(
1 +
φ
λitlit
)
−1)
,
µ|· ∼Normal
(∑N
i=1 1
τ
Σ
−1
i logλi∑N
i=1 1
τΣ
−1
i 1
,
(
N∑
i=1
1
τ
Σ
−1
i 1
)
−1)
,
σ2|· ∼ Inverse Gamma
(
1
2
∑
i
Ti,
[
1
2
N∑
i=1
(logλi −µi)
τR−1i (logλi −µi)
]
−1)
.
A random-walk style Metropolis–Hastings algorithm is used to sample ρ,
φ, α, β, γ, p0 and θ, that is, a new value is sampled from a normal density
with the current value as its mean. The variance of each proposal normal
density is dynamically adapted to reach an acceptance rate of 0.3–0.4. To
apply this sampling scheme, appropriate transformation may be necessary
so that the domain of the transformed parameter is (−∞,∞), for example,
a logit transformation for the transmission probability.
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Diagnostics for convergence. We run three chains simultaneously and
use the scale reduction factor to monitor the convergence of the chains. The
scale reduction factor is defined as
√
Rˆ=
√
M − 1
M
+
1
M
B
W
,
whereM is the number of runs, and B andW are the between-sequence and
within-sequence variances, respectively. Gelman and Rubin (1992) showed
that the factor
√
Rˆ will approach 1 as M →∞, and recommended that the
convergence can be considered as reached if
√
Rˆ < 1.2 for all parameters. We
calculate
√
Rˆ for each 5000 iterations afterward and the criteria
√
Rˆ < 1.2
is adopted as the stopping rule.
The results of analyzing the two AIDSVAX trials are based on the last
5000 iterations of three parallel chains. A burn-in period of 5000 runs is
enforced after the variances of proposal normal densities are fixed. To reduce
the correlation within each successive chain, we loop over the last 5000 runs
of the three parallel chains, and at each loop we randomly pick one chain to
read in the samples.
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